Medigene AG today announced its participation at the following upcoming investor and scientific conferences
Martinsried/Munich (pta/20.11.2018/07:30) MediGene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming investor and scientific conferences:
Bryan Garnier Healthcare Conference
Date: 22 - 23 November 2018
Location: Paris, France
45th ISOBM Congress (International Society of Oncology & BioMarkers)
Date: 24 - 27 November 2018
Location: Hamburg
German Equity Forum
Date: 26 - 28 November 2018
Location: Frankfurt, Germany
Dr Kai Pinkernell, CMO and CDO of Medigene AG, will give a company presentation on 26 November at 5 pm.
American Society for Hematology (ASH) Annual Meeting
Date: 1 - 4 December 2018
Location: San Diego, USA
In addition to Medigene participating at the conference, Medigene’s partner Oslo University Hospital will present a poster on their compassionate use data of five AML patients receiving their DC vaccines partially using Medigene’s DC vaccine technologies (December 2, 2018, 6:00 PM - 8:00 PM in Hall GH). To view the abstract of the poster entitled “Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use"" please visit: https://ash.confex.com/ash/
Cell Therapy Manufacturing & Gene Therapy Congress
Date: 4 - 6 December 2018
Location: Amsterdam, The Netherlands
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com
